Loading
Immunotherapy and Immune Responses / Vaccines and Immunoinformatics Approaches · Journal article
Frontiers in Genetics · July 28, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review examining the theoretical and computational role of artificial intelligence and machine learning in peptide cancer vaccine development, from neoantigen discovery through immunogenicity prediction. The review identifies current capabilities and limitations but does not report original empirical evidence, clinical trial results, or comparative effectiveness. It represents a synthesis of the current state of AI application in this domain rather than validation of any specific prediction model or clinical outcome.
Narrative review.
AI including machine learning and deep learning can integrate and analyze genomic, transcriptomic, proteomic, and immunological data to address vaccine development challenges. Current AI frameworks address neoantigen discovery, epitope prioritization, peptide–HLA binding prediction, antigen presentation, and T-cell receptor recognition. Significant barriers remain: high false-positive prediction rates, limited diversity of training datasets, biological complexity of immunogenicity, and regulatory and manufacturing barriers for individualized therapies.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a narrative review summarizing AI tools and their computational promise in cancer vaccine design, without reporting original empirical results, clinical outcomes, or comparative effectiveness data.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Peptide-based cancer vaccines represent a promising immunotherapeutic strategy aimed at inducing tumor-specific immune responses through the targeting of tumor-associated antigens and neoantigens. Recent advances in next-generation sequencing and immunogenomics have accelerated the identification of candidate neoantigens; however, the development of effective peptide vaccines remains limited by challenges related to antigen selection, HLA polymorphism, antigen processing, and variability in immunogenicity. Artificial intelligence (AI), including machine learning and deep learning approaches, has emerged as a transformative tool capable of addressing these limitations through large-scale integration and analysis of genomic, transcriptomic, proteomic, and immunological data. In this review, we summarize the current role of AI across the peptide cancer vaccine development pipeline, from neoantigen discovery and epitope prioritization to prediction of peptide–HLA binding, antigen presentation, and T-cell receptor recognition. We discuss the application of modern computational frameworks, including pan-allelic prediction models, transformer-based architectures, immunopeptidomics-informed learning, and multi-modal AI systems integrating tumor and immune microenvironment data. Furthermore, we examine the clinical translation of personalized neoantigen vaccines, including their combination with immune checkpoint inhibitors and their emerging role in aggressive malignancies such as glioblastoma. Despite substantial progress, significant challenges remain, including high false-positive prediction rates, limited diversity of training datasets, biological complexity of immunogenicity, and regulatory and manufacturing barriers associated with individualized therapies. Continued integration of AI-driven prediction tools with experimental validation and translational immunology will be essential for the development of clinically effective and scalable precision cancer vaccines.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.